Chuangxin International Secures Nearly RMB 100 Million Series A Funding to Advance Organoid R&D and Industrialization

Recently,ACCURATE BIOTECHNOLOGY, a company dedicated to the research and development as well as industrialization of organoid technologies (hereinafter referred to as “ACCURATE BIOTECHNOLOGY”), announced the completion of its Series A financing round, raising nearly RMB 100 million.Led by Qudao Assets. The funding will primarily be used to advance the R&D upgrade and industrialization of organoids.

Headquartered in Guangzhou, ACCURATE BIOTECHNOLOGY is an innovative biomedical enterprise centered on organoid technology, comprising the China-Europe Organoid Research Institute, a third-party medical laboratory, and an organoid R&D technology platform.

ACCURATE BIOTECHNOLOGY is dedicated to three key areas: personalized clinical treatment, new drug development, and regenerative medicine. The company possesses a complete organoid industry chain, has established R&D centers in Beijing, Guangzhou, Shanghai, Macau, and Milan, Italy, and has conducted clinical and scientific research collaborations with over 60 core hospitals across China, while establishing laboratories in 10 major cities.

Organoids are 3D cell cultures derived from adult stem cells in vitro, exhibiting histological features highly similar to those of corresponding human organs and capable of recapitulating partial physiological functions.As a cutting-edge in vitro model, organoids hold broad application prospects across multiple fields, including stem cell and developmental biology, regenerative medicine, disease research, drug development, and precision medicine.In 2017, organoids were named Nature’s Method of the Year in the life sciences.

China officially began its strategic deployment of precision medicine in 2016. That year, the National Expert Advisory Group on Precision Medicine Strategy was established, with a plan to invest RMB 60 billion by 2030, thereby elevating precision medicine to the status of a “national strategy.” In 2021, according to documents issued by the Ministry of Science and Technology, “Stem Cell-Based Models for Major Refractory Human Diseases” was included among the first batch of key special projects under the 14th Five-Year Plan. The documents pointed out that organoids, as an important emerging frontier technology, can facilitate disease research and treatment.

Furthermore, globally renowned pharmaceutical companies have successively undertaken the application and development of organoid technology, with the U.S. FDA recognizing organoids as models for drug safety evaluation and new drug development.

ACCURATE BIOTECHNOLOGY is dedicated to building a complete organoid industry chain and establishing technical standards by providing precise and comprehensive solutions for precision medicine in oncology, new drug development, and basic research. As one of the earliest pioneers in the organoid field, it is also among the first companies in China to obtain invention patents for organoid technology.

An excellent R&D, medical, and operational management team has laid a solid foundation for the company’s development. InChief Scientist, Professor Deng ChuxiaUnder the leadership of, ACCURATE BIOTECHNOLOGY’s R&D team has established a comprehensive organoid culture and technical system, and has entered into global strategic collaborations with multinational corporations.

ACCURATE BIOTECHNOLOGY has been honored with the title of “2019 Leading Entrepreneurial Team,” recognized as a “2020 Technologically Innovative Small and Medium-sized Enterprise” by the Torch Center of the Ministry of Science and Technology, and certified as a National High-Tech Enterprise. In 2020, ACCURATE BIOTECHNOLOGY’s respiratory organoid technology, applied to coronavirus research, received project approval and support from the Guangdong Provincial and Municipal Departments of Science and Technology. ACCURATE BIOTECHNOLOGY also won the “Guangzhou High-Growth Tech Enterprise Rising Star” award and was selected as one of the Top 50 Potential and Emerging Enterprises in the Greater Bay Area.

The injection of nearly RMB 100 million in this round of financing will continue to accelerate ACCURATE BIOTECHNOLOGY’s R&D and industrial translation of organoid technology.

Qudao Asset stated, “The precision medicine sector represents a vast market, with organoid technology increasingly applied in precise tumor diagnosis and new drug development. ACCURATE BIOTECHNOLOGY is a platform-oriented enterprise that has rapidly advanced the industrialization of organoid technology in China. It has made strategic layouts across raw materials, reagents, and intelligent systems, driven by both R&D and market demands. The company is also actively advancing technology translation and clinical applications, participating in the exploration and drafting of organoid technology standards, while providing high-quality, full-industry-chain solutions to research institutions, pharmaceutical R&D organizations, and clinical experts. Its founding team possesses deep industry expertise, a strong global perspective, and robust overall execution capabilities. ACCURATE BIOTECHNOLOGY shares significant synergistic value with Qudao Asset, and we firmly believe it will grow into an industry leader in organoid technology.”

Guangzhou Qudao Asset Management Co., Ltd. (“Qudao Asset”) is a professional private equity investment fund focused on the healthcare industry. Its investors include multiple publicly listed healthcare companies, government guidance funds, and overseas investors, such as Daan Gene, Hengji Daxin, Boji Medicine, and South China New Drug. The fund’s industrial resources extensively cover in vitro diagnostics (IVD), new drug R&D, and CRO/CMO services. Leveraging its team’s extensive industry experience and resource network, Qudao Asset provides portfolio companies with strategic resources and capital market support through industrial chain integration, strategic M&A, and equity investments.